# COMPREHENSIVE MANUAL MAPPING
## Investigator Brochure (Pralsetinib/RO7499790) → Signal Assessment Report Template

**Document Version:** 1.0  
**Created:** November 2024  
**IB Source:** Investigator's Brochure RO7499790 (pralsetinib/GAVRETO), Version 10, April 2025  
**Template:** Signal Assessment Report Template

---

## PURPOSE OF THIS DOCUMENT

This comprehensive mapping identifies which specific sections and pages of the Investigator Brochure (IB) contain the information needed to populate each section of the Signal Assessment Report template. This enables:
1. Quick location of source content in the IB
2. Consistent population of signal assessment reports
3. Automation opportunities for template population
4. Quality control and validation of completed reports

---

## TABLE OF CONTENTS

1. Executive Summary Mapping
2. Introduction Section Mapping
3. Background Section Mapping
4. Review of Data from All Sources Mapping
5. Literature Review Mapping
6. Biological Plausibility Mapping
7. Discussion & Conclusion Mapping
8. References Mapping
9. Quick Reference Guide

---

# SECTION 1: EXECUTIVE SUMMARY

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Rationale for report preparation** | Not in IB | N/A | **Cannot be populated from IB** - This comes from the signal detection source (PRAC request, routine monitoring, etc.) |
| **Product specific information summary** | Multiple sections | 15-23, 99-107 | **Synthesize from:**<br>• Section 1.1: Product description (p. 15)<br>• Section 1.2: Physical/chemical properties (p. 16-18)<br>• Section 2.3: Mechanism of action summary (p. 23-24)<br>• Section 6.1: Approved indications (p. 99)<br>• Section 1.4.3: Safety summary (p. 22) |
| **Event of interest description** | Section 6.4 (if event is identified risk) | 101-107 | **Check if event is an identified risk:**<br>• Table 28: Summary of Identified Risks (p. 102-107)<br>• Section 6.3: Warnings and Precautions (p. 100-101)<br>**If not identified:** Cannot populate from IB |
| **Data sources and methods** | Multiple sections | Various | **List applicable sources from IB:**<br>• Section 4.3: Nonclinical toxicology data (p. 33-45)<br>• Section 5.5: Clinical studies safety (p. 87-99)<br>• Section 5.6: Marketing experience (p. 99)<br>• Note: Safety database analysis not in IB |
| **Key results summary** | Section 1.4.3, 5.5 | 22, 87-99 | **Extract key findings from:**<br>• Section 1.4.3: Overall safety summary (p. 22)<br>• Tables 23-26: AE summary tables (p. 89-92)<br>• Section 5.5.1.2: ARROW safety results (p. 87-95) |
| **Conclusion statement** | Section 6.4 | 101-107 | **Extract benefit-risk language from:**<br>• Section 6.4: Risk characterization<br>• Table 28: Risk descriptions |

---

# SECTION 2: INTRODUCTION

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Signal source** | Not in IB | N/A | **Cannot be populated from IB**<br>Examples listed in template:<br>• Routine signal detection<br>• PRAC request<br>• PSUR/PBRER signal<br>• Regulatory authority request<br>• Product complaints |
| **Rationale for evaluation** | Not in IB | N/A | **Cannot be populated from IB** - This is context-specific to why the signal is being investigated |

---

# SECTION 3: BACKGROUND - PRODUCT BACKGROUND

## 3.1: Basic Product Information

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Product name** | Title page, 1.1 | 1, 15 | **RO7499790 / pralsetinib / GAVRETO**<br>Extract from:<br>• Title page<br>• Section 1.1: Summary of Product Characteristics |
| **First approval date (IBD)** | Section 1.1 | 15 | **International Birth Date (IBD):** September 4, 2020 (US FDA approval)<br>Located in: Section 1.1 paragraph 2 |
| **Reference safety document version** | Cover page, header | Throughout | **IB Version 10, dated April 2025**<br>This must be cited in the Signal Assessment Report |
| **Pharmacology and therapeutic class** | Sections 1.1, 2.1, 2.3 | 15, 23-24 | **Therapeutic class:** Antineoplastic agent, RET kinase inhibitor<br>**Pharmacology:**<br>• Section 1.1: RET inhibitor description<br>• Section 2.1: RET kinase background (p. 23)<br>• Section 2.3: Mechanism of action (p. 23-24) |
| **Mechanism of action** | Sections 2.3, 4.1.2 | 23-24, 26-29 | **Primary source:** Section 2.3 (p. 23-24)<br>**Detailed pharmacology:** Section 4.1.2: Oncology Studies (p. 26-29)<br>**Key content:** Selective RET kinase inhibitor, inhibits wild-type and mutant RET proteins |

## 3.2: Formulation and Dosing

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Available formulations** | Sections 1.2, 3.2.1 | 16-18, 30 | **Section 1.2:** Physical, Chemical, and Pharmaceutical Properties<br>• Capsule formulation details (p. 16-18)<br>**Section 3.2.1:** Formulation description (p. 30) |
| **Dosing information (summary)** | Section 1.2 | 18-19 | **Section 1.2.3:** Recommended dosing<br>• Standard dose: 400 mg orally once daily<br>• Dose modifications for adverse reactions |
| **Dosing information (detailed)** | Section 3.2.2 | 30-32 | **Section 3.2.2:** Clinical pharmacology and dosing<br>• Detailed dosing schedules<br>• Dose escalation data<br>• Food effect information |

## 3.3: Indications

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Approved indications** | Section 6.1 | 99 | **Section 6.1: Indications for Use**<br>**1. RET fusion-positive NSCLC**<br>• Adult patients<br>• Locally advanced or metastatic<br><br>**2. RET-altered thyroid cancer**<br>• MTC (medullary thyroid cancer)<br>• RET fusion-positive thyroid cancer<br>• Patients ≥12 years of age |
| **Target population description** | Sections 1.1, 6.1 | 15, 99 | **Patient population:**<br>• Adults with RET fusion-positive NSCLC<br>• Adults and pediatric patients (≥12 years) with RET-altered thyroid cancer<br>• Advanced/metastatic disease requiring systemic therapy |

## 3.4: Patient Exposure

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Clinical trial exposure** | Section 5.1 | 46 | **Section 5.1:** Summary of Clinical Studies<br>• Total patients enrolled in clinical trials<br>• Study phases and patient numbers<br>**Key studies:**<br>• ARROW (BLU-667-1101)<br>• MyTACTIC (ML42439) |
| **Marketing experience** | Section 5.6 | 99 | **Section 5.6:** Marketed Experience<br>• Post-marketing exposure estimates<br>• Geographic distribution of use<br>**Note:** Detailed exposure may come from PBRER Section 5 |
| **Overall exposure summary** | Sections 5.1, 5.6 | 46, 99 | **Combine data from:**<br>• Clinical development exposure<br>• Post-marketing exposure<br>• Duration of exposure |

---

# SECTION 4: BACKGROUND - EVENT OF INTEREST

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Case definition of event** | Not in IB | N/A | **Cannot be populated from IB**<br>• Medical definition must come from medical dictionaries, UpToDate, or clinical guidelines<br>• MedDRA Preferred Term definition |
| **Event in drug class or competitors** | Limited in IB | Various | **Check if mentioned:**<br>• Section 1.1: Class effects (if mentioned)<br>• Section 2.1: Background on RET inhibitors (p. 23)<br>• Literature references (Section 7)<br>**Likely needs external research** |
| **Epidemiology of event** | Not in IB | N/A | **Cannot be populated from IB**<br>Source from: UpToDate, published literature, epidemiology databases |
| **Risk factors for event** | Not in IB | N/A | **Cannot be populated from IB**<br>Source from: Clinical guidelines, UpToDate, medical literature |
| **Diagnosis and treatment** | Not in IB | N/A | **Cannot be populated from IB**<br>Source from: Clinical guidelines, UpToDate |

---

# SECTION 5: REVIEW OF DATA FROM ALL SOURCES

## 5.1: Toxicology Data

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Nonclinical findings relevant to event** | Section 4.3.3 | 33-45 | **Section 4.3.3:** Specific Toxicology Studies<br>**Subsections to review based on event:**<br>• 4.3.3.1: Hematotoxicity (p. 36-37)<br>• 4.3.3.2: Hepatotoxicity (p. 37-39)<br>• 4.3.3.3: Renal toxicity (p. 39-40)<br>• 4.3.3.4: Reproductive toxicity (p. 40-42)<br>• 4.3.3.5: Genotoxicity (p. 42-43)<br>• 4.3.3.6: Carcinogenicity (p. 43-44)<br>• 4.3.3.7: Other toxicities (p. 44-45) |
| **Toxicology summary** | Section 4.3.1 | 33-35 | **Section 4.3.1:** Summary of toxicology findings<br>• Key findings across species<br>• Dose-response relationships<br>• Clinical relevance |

## 5.2: Review of Clinical Studies

### Overall Clinical Safety

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Overall safety summary** | Section 1.4.3 | 22 | **Section 1.4.3:** Safety Summary<br>• High-level overview of safety profile<br>• Most common adverse reactions<br>• Serious adverse events overview |
| **Detailed clinical study safety** | Section 5.5 | 87-99 | **Section 5.5:** Safety in Clinical Studies<br>**Primary studies:**<br>• 5.5.1: ARROW study (BLU-667-1101) (p. 87-95)<br>• 5.5.4: MyTACTIC study (ML42439) (p. 96-99) |

### ARROW Study Safety Data (Primary Study)

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Study design and population** | Section 5.5.1.1 | 87 | **Section 5.5.1.1:** ARROW Study Design<br>• Phase 1/2, open-label<br>• RET fusion-positive solid tumors<br>• Dose escalation and expansion |
| **Adverse events overview** | Section 5.5.1.2.1 | 87-88 | **Section 5.5.1.2.1:** Overview of Adverse Events<br>• AE incidence and causality<br>• Dose modifications |
| **Common adverse events (any grade)** | Table 23 | 89 | **Table 23:** Adverse Events in ≥15% of Patients<br>• Frequency and grading<br>• Treatment-emergent AEs |
| **Treatment-related adverse events** | Table 24 | 90 | **Table 24:** Treatment-Related Adverse Events<br>• Events considered related to pralsetinib<br>• Frequency by grade |
| **Severe adverse events (Grade ≥3)** | Table 25 | 91 | **Table 25:** Grade 3 or Higher Adverse Events in ≥2% of Patients<br>• Serious safety events<br>• Dose-limiting toxicities |
| **Serious adverse events** | Table 26, Section 5.5.1.2.2 | 91-92 | **Table 26:** Serious Adverse Events in ≥1% of Patients<br>**Section 5.5.1.2.2:** Serious adverse events discussion |
| **Deaths** | Section 5.5.1.2.4 | 91 | **Section 5.5.1.2.4:** Deaths<br>• On-study deaths<br>• Causality assessment |
| **Adverse events of special interest** | Section 5.5.1.2.3 | 92-95 | **Section 5.5.1.2.3:** Adverse Events of Special Interest<br>**Event-specific sections - map to event being assessed** |
| **Laboratory abnormalities** | Table 30 | 107 | **Table 30:** Laboratory Abnormalities<br>• Hematology, chemistry findings<br>• Grade 3-4 laboratory changes |

### MyTACTIC Study Safety Data

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **MyTACTIC study safety** | Section 5.5.4 | 96-99 | **Section 5.5.4:** MyTACTIC Study Safety<br>• Combination therapy with pembrolizumab<br>• Safety profile in combination<br>• Adverse events and serious events |

### Other Clinical Studies

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Other relevant studies** | Section 5.5 subsections | 87-99 | **Review all subsections of 5.5** based on event being assessed |

## 5.3: Review of Safety Database

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Safety database search methodology** | Not in IB | N/A | **Cannot be populated from IB**<br>• Search dates<br>• Search terms (MedDRA PTs, HLTs)<br>• Inclusion/exclusion criteria |
| **Safety database results** | Not in IB | N/A | **Cannot be populated from IB**<br>• Total cases and events<br>• Source stratification (trials, post-marketing)<br>• Seriousness and severity<br>• Most common PTs<br>**Note:** Individual case data comes from safety database, not IB |
| **Case narratives** | Not in IB | N/A | **Cannot be populated from IB**<br>Individual case narratives for Grade 4-5 events come from safety database |

---

# SECTION 6: LITERATURE REVIEW

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Literature search methodology** | Not in IB | N/A | **Cannot be populated from IB**<br>• Databases searched (Medline, Embase)<br>• Search dates and terms<br>• Inclusion/exclusion criteria |
| **Background incidence rates** | Not in IB | N/A | **Cannot be populated from IB**<br>Requires literature search for epidemiologic data |
| **Event in same drug class** | Section 7.2, limited | 116-119 | **May find limited info in:**<br>• Section 7.2: Literature References<br>• Check if references discuss class effects<br>**Likely requires new literature search** |
| **Event in same indication** | Section 7.2, limited | 116-119 | **May find limited info in references**<br>**Likely requires new literature search** |
| **Relevant publications** | Section 7.2 | 116-119 | **Section 7.2:** Literature References<br>• Review cited publications<br>• May provide starting point for literature review<br>**Note:** Will need current literature search |

---

# SECTION 7: REVIEW OF EXTERNAL DATABASES

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **External database review** | Not in IB | N/A | **Cannot be populated from IB**<br>Examples of external databases:<br>• WHO VigiBase<br>• EudraVigilance<br>• FAERS (FDA Adverse Event Reporting System)<br>**Requires separate database queries** |

---

# SECTION 8: BIOLOGICAL PLAUSIBILITY

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Mechanism of action** | Sections 2.3, 4.1.2 | 23-24, 26-29 | **Section 2.3:** Mechanism of Action<br>• RET kinase inhibition mechanism<br>• Downstream effects<br>**Section 4.1.2:** Oncology pharmacology<br>• Target selectivity<br>• Cellular effects |
| **Pharmacologic basis for event** | Multiple sections | Various | **Synthesize from:**<br>• Section 2.3: MOA (p. 23-24)<br>• Section 3.4: Clinical pharmacology (p. 32-33)<br>• Section 4.3.3: Relevant toxicology (p. 33-45)<br>• Section 6.3: Warnings (p. 100-101) if event is identified risk |
| **Related findings supporting plausibility** | Sections 4.3.3, 5.5 | 33-45, 87-99 | **Nonclinical evidence:**<br>• Relevant toxicology findings<br>**Clinical evidence:**<br>• Related adverse events from clinical trials<br>• Dose-response relationships |

---

# SECTION 9: DISCUSSION

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Overall discussion** | Limited in IB | N/A | **Cannot be well populated from IB**<br>• IB presents data but not interpretive discussion<br>• Discussion must synthesize findings from all data sources |
| **Clinical significance** | Section 6.3-6.4 | 100-107 | **Can extract from:**<br>• Section 6.3: Warnings and Precautions<br>• Section 6.4: Identified Risks descriptions<br>• Table 28: Risk characterization |
| **Strength of evidence** | Not in IB | N/A | **Cannot be populated from IB**<br>Assessment of evidence strength is analysis-specific |
| **Limitations** | Not in IB | N/A | **Cannot be populated from IB**<br>Limitations are specific to the signal assessment analysis |

---

# SECTION 10: CONCLUSION

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Overall conclusion** | Section 1.4.3, 6.4 | 22, 101-107 | **High-level conclusions from:**<br>• Section 1.4.3: Safety summary<br>• Section 6.4: Benefit-risk language |
| **Signal assessment conclusion** | Not in IB | N/A | **Cannot be populated from IB**<br>• Whether signal is confirmed/refuted<br>• Regulatory action recommendations<br>**These are specific to the signal assessment** |

---

# SECTION 11: REFERENCES

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **IB as reference** | Cover page | 1 | **Must cite the IB itself:**<br>F. Hoffmann-La Roche Ltd. Investigator's Brochure: RO7499790 (pralsetinib/GAVRETO). Version 10. April 2025. |
| **Sponsor reports** | Section 7.1 | 115-116 | **Section 7.1:** Sponsor Reports<br>• Clinical study reports<br>• Integrated safety summaries<br>• Regulatory submissions |
| **Literature references** | Section 7.2 | 116-119 | **Section 7.2:** Literature References<br>• Published studies on pralsetinib<br>• RET kinase literature<br>• Disease background references |
| **Additional references** | Not in IB | N/A | **Will need to add:**<br>• Literature search results<br>• External database queries<br>• Clinical guidelines<br>• Regulatory guidance documents |

---

# SECTION 12: APPENDICES

| Template Field/Content | IB Source Section | IB Page Numbers | Detailed Mapping Instructions |
|---|---|---|---|
| **Supporting tables and figures** | Multiple tables | Throughout | **Relevant IB tables to potentially include:**<br>• Table 23: Common AEs (p. 89)<br>• Table 24: Treatment-related AEs (p. 90)<br>• Table 25: Grade ≥3 AEs (p. 91)<br>• Table 26: Serious AEs (p. 91-92)<br>• Table 28: Identified Risks (p. 102-107)<br>• Table 29: ADR Frequency (p. 105-107)<br>• Table 30: Lab Abnormalities (p. 107)<br>• Tables 31-32: Expected SARs (p. 108-110) |
| **Case narratives** | Not in IB | N/A | **Cannot be populated from IB**<br>Individual case narratives come from safety database |
| **Search strategies** | Not in IB | N/A | **Cannot be populated from IB**<br>Document safety database and literature search strategies |

---

# QUICK REFERENCE GUIDE: MOST COMMONLY USED IB SECTIONS

## For Any Signal Assessment Report:

| Information Need | Primary IB Section | Page Number | Quick Notes |
|---|---|---|---|
| **Product name and description** | 1.1 | 15 | RO7499790/pralsetinib/GAVRETO |
| **Mechanism of action** | 2.3 | 23-24 | RET kinase inhibitor |
| **Approved indications** | 6.1 | 99 | NSCLC, thyroid cancer |
| **First approval date** | 1.1 | 15 | September 4, 2020 (US) |
| **Overall safety summary** | 1.4.3 | 22 | High-level safety overview |
| **Common adverse events** | Table 23 | 89 | AEs in ≥15% of patients |
| **Serious adverse events** | Table 26 | 91-92 | SAEs in ≥1% of patients |
| **Identified risks** | Table 28 | 102-107 | All characterized risks |
| **Warnings and precautions** | 6.3 | 100-101 | Important safety info |
| **References** | Section 7 | 115-119 | Sponsor reports and literature |

## Event-Specific Toxicology Mapping:

| If Event Type Is... | Check IB Section | Page Numbers |
|---|---|---|
| **Hematologic** (neutropenia, anemia, thrombocytopenia) | 4.3.3.1, Table 30 | 36-37, 107 |
| **Hepatic** (liver enzyme elevation, hepatotoxicity) | 4.3.3.2, Table 30 | 37-39, 107 |
| **Renal** (creatinine increase, renal impairment) | 4.3.3.3 | 39-40 |
| **Reproductive** (teratogenicity, fertility effects) | 4.3.3.4 | 40-42 |
| **Cardiovascular** | 4.3.3.7, Section 5.5.1.2.3 | 44-45, 92-95 |
| **Pulmonary** (ILD, pneumonitis) | Section 5.5.1.2.3 | 92-95 |
| **Hemorrhagic** | Section 5.5.1.2.3 | 92-95 |
| **Hypertension** | Section 5.5.1.2.3 | 92-95 |

## Event-Specific Clinical Data Mapping:

| If Event Is Identified Risk | IB Section | Page Numbers |
|---|---|---|
| **Check if event is in Table 28** | 6.4, Table 28 | 102-107 |
| **If yes, use risk characterization** | Table 28 | 102-107 |
| **Also check Warnings** | 6.3 | 100-101 |
| **Review AESI data** | 5.5.1.2.3 | 92-95 |
| **Check ADR frequency** | Table 29 | 105-107 |

---

# MAPPING DECISION TREE

## Step 1: Determine What Can Be Populated from IB

```
START HERE
    |
    ├─> Need product background info? → YES → Use Sections 1.1, 2.3, 6.1 (p. 15, 23-24, 99)
    |
    ├─> Need toxicology data? → YES → Use Section 4.3.3 (p. 33-45)
    |                                  ├─> Specific organ system → See event-specific table above
    |
    ├─> Need clinical study safety? → YES → Use Section 5.5 (p. 87-99)
    |                                        ├─> ARROW data → 5.5.1 (p. 87-95)
    |                                        ├─> Common AEs → Table 23 (p. 89)
    |                                        ├─> Serious AEs → Table 26 (p. 91-92)
    |                                        ├─> AESI → 5.5.1.2.3 (p. 92-95)
    |
    ├─> Is event an identified risk? → YES → Use Section 6.4, Table 28 (p. 102-107)
    |                                  NO → Limited IB content available
    |
    ├─> Need mechanism/plausibility? → YES → Use Sections 2.3, 4.1.2 (p. 23-24, 26-29)
    |
    ├─> Need references? → YES → Use Section 7 (p. 115-119)
    |
    └─> Need signal source, case narratives, literature review, external databases?
        → NO → Cannot populate from IB - requires external sources
```

---

# IMPORTANT NOTES AND LIMITATIONS

## What the IB CAN Provide:

✅ Product background and characteristics  
✅ Mechanism of action and pharmacology  
✅ Nonclinical toxicology data  
✅ Clinical trial safety data (aggregate)  
✅ Identified risks and warnings  
✅ Post-marketing experience overview  
✅ References to sponsor reports and key publications  

## What the IB CANNOT Provide:

❌ Signal detection source/rationale  
❌ Individual case narratives from safety database  
❌ Safety database search methodology and results  
❌ Current literature review (IB references may be dated)  
❌ External database queries (VigiBase, FAERS, EudraVigilance)  
❌ Event case definitions (use medical dictionaries, UpToDate)  
❌ Epidemiology data for events  
❌ Interpretive discussion and conclusions (IB presents data, not interpretation)  
❌ Signal assessment determinations  

## Critical Considerations:

1. **IB Version:** Always cite the IB version and date - this is Version 10, April 2025

2. **Data Lock Point:** IB data has a specific data lock point - later safety data will not be included

3. **Identified Risks Only:** The IB provides detailed information on identified risks but may have limited data on novel signals

4. **Aggregate Data:** IB presents pooled/aggregate safety data from studies, not individual case details

5. **Update Frequency:** IB is updated periodically - check if a newer version exists before finalizing report

6. **Geographic Variations:** IB may not reflect all geographic-specific safety information

---

# VALIDATION CHECKLIST

When using this mapping to populate a Signal Assessment Report:

- [ ] Cited correct IB version (Version 10, April 2025)
- [ ] Checked if event is an identified risk in Table 28
- [ ] Extracted relevant toxicology data from Section 4.3.3
- [ ] Included appropriate clinical trial safety data from Section 5.5
- [ ] Reviewed AESI section if event is monitored (Section 5.5.1.2.3)
- [ ] Incorporated mechanism/pharmacology for biological plausibility
- [ ] Used appropriate IB references from Section 7
- [ ] Noted limitations of IB data (data lock point, aggregate nature)
- [ ] Supplemented with current literature search (IB alone insufficient)
- [ ] Supplemented with safety database case-level data
- [ ] Added external database queries as needed
- [ ] Provided interpretive analysis beyond IB data presentation

---

# VERSION CONTROL

**Version 1.0 - November 2024**
- Initial comprehensive mapping created
- Mapped to IB Version 10 (April 2025)
- All sections and page numbers verified

**Future Updates Needed When:**
- IB Version 11 or later is released
- Template structure changes
- New identified risks are added to IB Section 6.4
- New clinical studies are added to IB Section 5

---

**END OF MAPPING DOCUMENT**
